Agenus Inc AGEN

$8.36 +0.03 (0.36%)

Valuation

Market cap
376,199,000
Revenue TTM
$114,200,000
Net income TTM
$120,000
PE ratio
2.83
Forward PE
—
Profit margin
0.11%
Debt to equity
-0.15

Trading

Volume
1,085,500
Avg volume
1,286,544
Day's range
$8.08 – $8.61
Shares out
45,162,000
Stochastic %K
13%
Beta
1.31
Analysts
Strong Sell
Price target
$21.40

Price

Company profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also d...

Show more

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 674 4400
Website
https://www.agenusbio.com
Address
3 Forbes Road, Lexington, United States

Latest news

Stocktwits

getreal369 Oct 3, 10:52 PM
$AGEN including platinum-resistant patients at 47% three-year survival VERY important!!
0 replies
DownATon Oct 3, 8:21 PM
$AGEN zack must be excited, took the time to email us
0 replies
pedmac2000 Oct 3, 8:19 PM
$AGEN https://cancerletter.com/white-house/20261002_2/
1 replies
A_I_R_IKAZEE Oct 3, 8:16 PM
$AGEN where are you all getting this 400 plus patients from, what trial are you referring?
1 replies
A_I_R_IKAZEE Oct 3, 7:33 PM
$AGEN N=35!!!! Rise and shine, dipshits. This thing is engineered to rip higher on Monday—and the entire run-up was meticulously architected by the short sellers themselves, with one solitary, glorious purpose in mind.
2 replies
joechuck71 Oct 3, 7:09 PM
$AGEN 48% with 400 patients not massive but not small either.
1 replies
Jcilip01 Oct 3, 5:57 PM
$AGEN this is really good news. Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer That shouldincrease our potential market cap significantly and in theory should convince the FDA to issue AA for two solid indications!
0 replies
anglesm Oct 3, 5:53 PM
$AGEN OK, Agenus' three-year follow-up results from the ovarian cancer cohort were good. Best care possible. And now doctors treating this cancer know. So, what is next: Will doctors and patients demand B&B treatment first? How will the FDA react NOW? How will the stock market treat Agenus come Monday? And why did the SP drop so deep on Thursday? Clearly insiders knew the results to be announced. Is it possible, insiders had already finished their purchases in the previous days, which pushed the SP to $10? But were absent on Thursday, and bargain hunters came in on Friday? Or is there more to last week's SP action? For example: Option players? Did shorts come in strong enough on Thursday to start a sell off? Clearly, long holders know not to set stop-loss orders. Right?
2 replies